RxDoctor Payments Data

Jose Sanchez, MD

Internal Medicine · San Antonio, TXNPI 1982600623

Payments from drug & device makers

$15,980in general payments, 2019–2025

Across 959 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • GSK$911
  • plus $6K from 54 others

What the payments were for

  • Travel & lodging$180%
  • Food & beverage$15,950100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca59$2,659
Novo Nordisk121$2,039
AbbVie(2 entities)91$1,890
Lilly USA, LLC144$1,275
Amgen84$1,170
GSK70$911
Johnson & Johnson(2 entities)58$700
Boehringer Ingelheim61$696
Pfizer47$489
Bayer13$401
Teva Pharmaceuticals USA, Inc.23$369
Merck32$366
Esperion Therapeutics, Inc.13$362
Intuitive Surgical3$241
Eisai Inc.16$234
Takeda Pharmaceuticals U.S.A., Inc.14$220
Corcept Therapeutics4$156
Stryker3$148
Sanofi-aventis U.S. LLC10$147
Astellas Pharma US Inc7$119
Amarin Pharma, Inc.7$108
Orthofix Medical, Inc.1$96
Biohaven Pharmaceuticals, Inc.5$93
Abbott5$86
Biohaven Pharmaceutical Holding Company Ltd.4$85
Phathom Pharmaceuticals, Inc.1$63
Supernus Pharmaceuticals, Inc.4$61
Gilead4$61
Regeneron Healthcare Solutions, Inc.2$60
Nevro Corp.2$55
Dynavax Technologies Corporation9$44
Althera Pharmaceuticals LLC5$39
Angiodynamics, Inc.1$38
Clarus Therapeutics Inc.3$35
Mannkind Corporation2$33
Currax Pharmaceuticals LLC4$29
Novartis2$28
Coloplast1$27
Exact Sciences1$25
Sumitomo Pharma America, Inc.1$23
Inari Medical, Inc.1$21
Dermira, Inc.1$19
Sunovion Pharmaceuticals Inc.1$19
Tris Pharma Inc1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Xeris Pharmaceuticals, Inc.1$16
Medtronic1$15
IBSA Pharma Inc.1$15
Antares Pharma, Inc.1$15
Nestle Healthcare Nutrition Inc.1$15
Avanir Pharmaceuticals, Inc.1$15
Neos Therapeutics, LP1$15
Lundbeck LLC1$14
Viiv Healthcare Company1$14
Ironshore Pharmaceuticals Inc.1$13
Kaleo, Inc.1$13
Nalpropion Pharmaceuticals LLC1$12
Genentech USA, Inc.1$12
Ironwood Pharmaceuticals, Inc1$11
Organon3$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,980 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$222,295
Medicare patients
662
Services billed
3,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$158,991
JardianceEmpagliflozin137$120,566
FarxigaDapagliflozin Propanediol56$44,574
TrulicityDulaglutide26$44,084
MounjaroTirzepatide34$34,147
AbrysvoRsv Vacc, Pref A And Pref B/Pf102$32,281
Breo ElliptaFluticasone/Vilanterol72$31,733
EliquisApixaban37$30,291
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,502
JanuviaSitagliptin Phosphate20$18,932
XareltoRivaroxaban20$17,663
TradjentaLinagliptin23$12,843
ShingrixVaricella-Zoster Ge/As01b/Pf50$11,273
Tresiba Flextouch U-100Insulin Degludec11$9,574
Advair HfaFluticasone Propion/Salmeterol14$7,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,039$158,991141 claims
Boehringer IngelheimJardiance, Tradjenta$696$133,410160 claims
Lilly USA, LLCTrulicity, Mounjaro$1,275$78,23160 claims
GSKBreo Ellipta, Trelegy Ellipta, Shingrix$911$64,508147 claims
PfizerAbrysvo, Eliquis$489$62,572139 claims
AstraZenecaFarxiga, Symbicort$2,659$51,20474 claims
MerckJanuvia$366$18,93220 claims
Johnson & JohnsonXarelto$700$17,66320 claims
AbbVieSynthroid$1,890$6,15454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →